Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Baxter
Colorcon
Boehringer Ingelheim
Moodys

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Neuropeptide Y

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Neuropeptide Y?

Neuropeptide Y is an investigational drug.

There have been 4 clinical trials for Neuropeptide Y. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, and Disease. The leading clinical trial sponsors are Westchester Medical Center, U.S. Army Medical Research and Development Command, and Vanderbilt University.

There are two hundred and fifty-five US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Neuropeptide Y
TitleSponsorPhase
Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress DisorderU.S. Army Medical Research and Development CommandPhase 1/Phase 2
Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress DisorderWestchester Medical CenterPhase 1/Phase 2
Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress DisorderNew York Medical CollegePhase 1/Phase 2

See all Neuropeptide Y clinical trials

Clinical Trial Summary for Neuropeptide Y

Top disease conditions for Neuropeptide Y
Top clinical trial sponsors for Neuropeptide Y

See all Neuropeptide Y clinical trials

US Patents for Neuropeptide Y

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Neuropeptide Y   Start Trial Neuropeptide Y-derived peptides University of Copenhagen (Copenhagen K, DK) N.ae butted.stved Hospital (N.ae butted.stved, DK)   Start Trial
Neuropeptide Y   Start Trial Methods for the treatment of kidney fibrosis THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (Boston, MA)   Start Trial
Neuropeptide Y   Start Trial Method using an Y1 receptor activator for treating an anticancer agent-induced nephrotoxic injury KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Medtronic
Merck
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.